Every week, Rinchem shares important articles and topics about chemical and gas logistics, industries we operate in, and the general global supply chain. In this week's review we discuss the outlook of the semiconductor process chemical market, the squeezing electronics ecosystem, and the impact of tariffs on U.S. pharma.
Keep reading to see this week's hot topics.
This week's stats
$19.5 billion- the valuation of the global semiconductor process chemicals market for 2025 FactMR
5-20%- estimated percentage price increase in consumer electronics in 2026 The Chosun Daily
Semiconductor Process Chemicals Market Forecast and Outlook 2026 to 2036
The semiconductor process chemicals market is a key segment within the semiconductor materials ecosystem, essential for wafer fabrication steps such as cleaning, etching, deposition, and planarization. Growing demand for advanced semiconductors with smaller geometry and higher performance is driving increased consumption of ultra-high-purity process chemistries across global fabs. Market expansion is supported by rising fab capacity, especially in Asia Pacific and North America, and by strategic supply chain localization efforts. Producers of acids, bases, photoresists, solvents, gases, and CMP slurries are competing on purity, consistency, and supply reliability, with long qualification cycles and strong integration with fab process recipes shaping competitive dynamics.
Semiconductor Supercycle Fuels Chipflation, Squeezing Electronics Ecosystem
The semiconductor industry’s current supercycle—driven by surging demand for memory and other chips, particularly for AI and advanced computing—has triggered “chipflation,” squeezing the wider electronics supply chain as rising memory costs force finished-product makers to demand price cuts from their suppliers. This cost pressure threatens profitability for component vendors and has broader implications for pricing and product strategies across consumer technology segments like displays and sensors, as the entire ecosystem grapples with tight supply and escalating input costs.
U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
The article explains how U.S. tariff policy and Most Favored Nation (MFN)–linked pricing reforms, initiated in late 2025 and evolving into early 2026, are reshaping pharmaceutical manufacturing and procurement strategies. A proposed 100% tariff on imported branded and patented drugs—unless companies build production facilities in the U.S.—has created structural risk for global supply chains, prompting accelerated investment in U.S. manufacturing and negotiated pricing-and-exemption agreements with the U.S. government. These developments mean that tariff exposure and MFN pricing commitments are now intertwined, influencing where companies locate production, how they structure contracts with contract research and manufacturing partners, and how they manage costs and supply risks across research, clinical development, and commercial operations. Successful firms are focusing on SKU-level tariff exposure mapping, securing domestic fill/finish capacity, incorporating tariff/MFN clauses in supplier agreements, and integrating procurement with broader pricing and policy governance to convert compliance challenges into supply resilience.
Get more articles like this in your inbox
Sign up for our monthly newsletter
Find more articles
Request a Quote
